

6 June 2011 EMA/HMPC/114583/2008 *Corr.* <sup>1</sup> Committee on Herbal Medicinal Products (HMPC)

# Community herbal monograph on *Hamamelis virginiana* L., cortex

#### Final

Discussion in Working Party on Community monographs and Community	May 2008
list (MLWP)	July 2008
	September 2008
	November 2008
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	6 November 2008
for consultation	
End of consultation (deadline for comments). Comments should be	15 March 2009
provided using this template to hmpc.secretariat@ema.europa.eu	
Rediscussion in Working Party on Community monographs and	May 2009
Community list (MLWP)	July 2009
	September 2009
	November 2009
Adoption by Committee on Herbal Medicinal Products (HMPC)	12 November 2009

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Hamamelis virginiana L.; Hamamelidis cortex; hamamelis bark

BG (bălgarski): Хамамелис, кора	LT (lietuvių kalba):
CS (čeština): Vilínová kůra	LV (latviešu valoda): Burvjlazdas miza
DA (dansk): Hamamelisbark	MT (malti): Qoxra tal-Ħamamelis
DE (Deutsch): Hamamelisrinde	NL (nederlands): Toverhazelaar
EL (elliniká): Φλοιός Αμαμελίδος	PL (polski): Kora oczaru
EN (English): Hamamelis Bark	PT (português): Hamamélia, casca
ES (espanol): Hamamelis, corteza de	RO (română): Scoarţă de hamamelis
ET (eesti keel): Nõiapuukoor	SK (slovenčina): Hamamelová kôra
FI (suomi):	SL (slovenščina): Skorja virginskega nepozebnika
FR (français): Hamamélis de Virginie (écorce d')	SV (svenska): Hamamelisbark
HU (magyar): Nagylevelű csodamogyoró kéreg	IS (íslenska):
IT (italiano): Amamelide corteccia	NO (norsk): Hamamelisbark

1 Changes introduced in June 2011 in substance names in EU languages and section 4.2.



## Community herbal monograph on Hamamelis virginiana L., cortex

### 1. Name of the medicinal product

To be specified for the individual finished product.

#### 2. Qualitative and quantitative composition<sup>2,3</sup>

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	Hamamelis virginiana L., cortex; Hamamelidis cortex (hamamelis bark)
	i) Herbal substance
	Not applicable
	ii) Herbal preparations
	- Dried comminuted herbal substance
	- Tincture (Ratio of herbal substance to extraction solvent 1:10), extraction solvent ethanol 45% v/v
	- Dry extract (DER 5-7.7:1), extraction solvent ethanol 30% m/m

#### 3. Pharmaceutical form

Well-established use	Traditional use
	Comminuted herbal substance for decoction for oromucosal and anorectal use.
	Herbal preparations in semi-solid dosage forms for cutaneous use.
	Herbal preparations in semi-solid or liquid dosage forms for anorectal use.
	Herbal preparations in solid dosage forms for rectal use.

<sup>2 &</sup>quot;Hamamelidis cortex" consists of the dried bark from the stems, branches and twigs of *Hamamelis virginiana* L. (Fam. Hamamelidaceae), collected in spring. It contains not less than 4.0% of hide-powder precipitable tannins, expressed as pyrogallol and calculated with reference to the dried drug.

3 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal

<sup>3</sup> The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

Well-established use	Traditional use
	Herbal preparations in liquid dosage forms for oromucosal use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

## 4. Clinical particulars

#### 4.1. Therapeutic indications

Well-established use	Traditional use
	a) Traditional herbal medicinal product for relief of minor skin inflammation and dryness of the skin.
	b) Traditional herbal medicinal product for symptomatic relief of itching and burning associated with haemorrhoids.
	c) Traditional herbal medicinal product used as a mouthwash and gargles for relief of minor inflammation of mucous membranes of the oral cavity.
	The product is a traditional herbal medicinal product for use in the specified indications exclusively based upon long-standing use.

#### 4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Indication a)
	Adolescents, adults and elderly
	<u>Cutaneous use</u>
	Tincture in a strength corresponding to 5-10% in semi-solid preparations, several times daily.
	Dry extract (5-7.7:1; ethanol 30% m/m) in a strength corresponding to 1.3% as an ointment, several times daily.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	and precautions for use').

Well-established use	Traditional use
	Indication b)
	Adults and elderly
	Anorectal use
	Tincture in a strength corresponding to 5-10% in semisolid and liquid preparations, several times daily.
	Comminuted herbal substance as a decoction: 5-10 g/250 ml, up to 3 times a day as impregnated dressings.
	Dry extract (5-7.7:1; ethanol 30% m/m) in a strength corresponding to 1.3% as an ointment, several times daily.
	Rectal use
	Suppositories containing 66 mg of dry extract (5-7.7:1; ethanol 30% m/m), one suppository two or three times daily.
	The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Indication c)
	Adolescents, adults and elderly
	Tincture (1:10), ethanol 45% v/v (diluted 1:3, with water): 2-4 ml, three times daily for gargles.
	Comminuted herbal substance to be used as a decoction, for gargles: 2-3 g up to 3 times daily.
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Indications a) and c)
	If the symptoms persist for more than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Well-established use	Traditional use
	Indication b)
	If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Cutaneous use.
	Oromucosal use.
	Rectal use.
	Anorectal use.

#### 4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance(s).

### 4.4. Special warnings and precautions for use

Well-established use	Traditional use
	Indication a)
	The cutaneous use in children under 12 years of age has not been established due to lack of adequate data.  Indication b)
	The use in children and adolescents under 18 years of age has not been established due to lack of data.
	If rectal bleeding occurs a doctor should be consulted.
	Indication c)
	The use in children under 12 years of age has not been established due to lack of data.
	If symptoms persist or worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	For tinctures the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

## 4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

#### 4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not
	been established. In the absence of sufficient data, the use during pregnancy and lactation is
	not recommended.

#### 4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8. Undesirable effects

Well-established use	Traditional use
	Allergic contact dermatitis has been reported. The frequency is not known.
	If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

#### 4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

## 5. Pharmacological properties

#### 5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

#### 5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

#### 5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product.
	Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

## 6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

## 7. Date of compilation/last revision

6 June 2011